AMP deaminase inhibitors. 2. Initial discovery of a non-nucleotide transition-state inhibitor series

Journal of Medicinal Chemistry

Volumn 43, Issue 8, 2000, Pages 1495-1507

  Bookser, Brett C ^a   Kasibhatla, Srinivas Rao ^a   Appleman, James R ^a   Erion, Mark D ^a  

^a Metabasis Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE MONOPHOSPHATE DEAMINASE; COFORMYCIN;

ARTICLE; CHEMICAL STRUCTURE; ENZYME INHIBITION; ISCHEMIA; LIPOPHILICITY; SYNTHESIS;

AMP DEAMINASE; ANIMALS; CATTLE; CELL MEMBRANE; CELLS, CULTURED; COFORMYCIN; ENDOTHELIUM; ENZYME INHIBITORS; ERYTHROCYTES; ISCHEMIA; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; RABBITS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034692172     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990447m     Document Type: Article

References (57)

1. For AMP Deaminase Inhibitors. 1, see: Erion, M. D.; Kasibhatla, S. R.; Bookser, B. C.; van Poelje, P. D.; Reddy, M. R.; Gruber, H. E.; Appleman, J. R. Discovery of AMP Mimetics that Exhibit High Inhibitory Potency and Specificity for AMP Deaminase. J. Am. Chem. Soc. 1999, 121, 308-319.
2. Skladanowski, A. C. In Myocardial Energy Metabolism; de Jong, J. W., Ed.; Martinus Nijhoff: Dordrecht, 1988; pp 53-65.
3. For lead references on adenosine-related therapeutics research, see: (a) Adenosine and Adenosine Receptors; Williams, M., Ed.; Humana Press: Clifton, NJ, 1990.
4. (b) Purinergic Approaches in Experimental Therapeutics; Jacobson, K. A., Jarvis, M. F., Eds.; Wiley-Liss: New York, 1997.
5. Loh, E.; Rebbeck, T. R.; Mahoney, P. D.; DeNofrio, D.; Swain, J. L.; Holmes, E. W. Common Variant in AMPD1 Gene Predicts Improved Clinical Outcome in Patients With Heart Failure. Circulation 1999, 99, 1422-1425.
6. In addition to its potential antiischemic uses, recent reports indicate AMPDA inhibitors may be worthwhile to investigate as herbicidal and anti-Alzheimer's agents: (a) Lindell, S. D.; Moloney, B. A.; Hewitt, B. D.; Earnshaw, C. G.; Dudfield, P. J.; Dancer, J. E. The Design and Synthesis of Inhibitors of Adenosine-5′-Phosphate Deaminase. Bioorg. Med. Chem. Lett. 1999, 9, 1985-1990.
7. (b) Sims, B.; Powers, R. E.; Sabina, R. L.; Theibert, A. B. Elevated Adenosine Monophosphate Deaminase Activity in Alzheimer's Disease Brain. Neurobiol. Aging 1998, 19, 385-391.
8. (a) Hapke, D. M.; Stegmann, A. P. A.; Mitchell, B. S. Retroviral Transfer of Deoxycytidine Kinase into Tumor Cell Lines Enhances Nucleoside Toxicity. Cancer Res. 1996, 56, 2343-2347.
9. (b) Maehara, Y.; Kusumoto, T.; Yasunori, E.; Anai, H.; Sakaguchi, Y.; Kohnoe, S.; Sugimachi, K. 5-Fluorouracil Is Converted to F-Nucleotides More Extensively and is More Cytotoxic in Poorly Differentiated than in Well Differentiated Human Gastric Carcinoma. Anticancer Res. 1990, 10, 1091-1094.
10. (a) Starrett, J. E., Jr.; Tortolani, D. R.; Hitchcock, M. J. M.; Martin, J. C.; Mansuri, M. M. Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine. Antiviral Res. 1992, 19, 267-273.
11. (b) Srivastva, D. N.; Farquhar, D. Bioreversible Phosphate Protective Groups: Synthesis and Stability of Model Acyloxymethyl Phosphates. Bioorg. Chem. 1984, 12, 118-129.
12. (c) Krise, J. P.; Stella, V. J. Prodrugs of phosphates, phosphonates and phosphinates. Adv. Drug Delivery Rev. 1996, 19, 287-310.
13. (d) Jones, R. J.; Bischofberger, N. Minireview: nucleotide prodrugs. Antiviral Res. 1995, 27, 1-17.
14. Isolation and identification: (a) Ohno, M.; Yagisawa, N.; Shibahara, S.; Kondo, S.; Maeda, K.; Umezawa, H. Structure of Coformycin, an Unusual Nucleoside of Microbial Origin. J. Am. Chem. Soc. 1974, 96, 4327-4328.
15. The 8R/S-isomer was prepared for this study according to literature methods: (b) Hawkins, L. D.; Hanvey, J. C.; Boyd, F. L. Jr.; Baker, D. C. Inhibitors of Adenosine Deaminase. Synthesis of Coformycin and 3′-Deoxycoformycin. Nucleosides Nucleotides 1983, 2, 479-494.
16. (c) Showalter, H. D. H.; Putt, S. R.; Baker, D. C. In Nucleic Acid Chemistry; Townsend, L. B., Tipson, R. S., Eds.; Wiley: New York, 1991; pp 308-313.
17. Frieden, C.; Kurz, L. C.; Gilbert, H. R. Adenosine Deaminase and Adenylate Deaminase: Comparative Kinetic Studies with Transition State and Ground-State Analogue Inhibitors. Biochemistry 1980, 19, 5303-5309.
18. 1-Adrenergic Stimulation. Circ. Res. 1989, 65, 754-760.
19. (b) Bennett, L. L., Jr.; Brockman, R. W.; Allan, P. W.; Rose, L. M.; Shaddix, S. C. Alterations in Nucleotide Pools Induced by 3-Deazaadenosine and Related Compounds Role of Adenylate Deaminase. Biochem. Pharmacol. 1988, 37, 1233-1244.
20. (c) Zoref-Shani, E.; Shainberg, A.; Sperling, O. Pathways of adenine nucleotide catabolism in primary rat muscle cultures. Biochim. Biophys. Acta 1987, 926, 287-295.
21. (d) Ashby, B.; Wernick, E.; Holmsen, H. Coformycin Inhibition of Platelet AMP Deaminase Has No Effect on Thrombin-induced Platelet Secretion nor on Glycolysis or Glycogenolysis. J. Biol. Chem. 1983, 258, 321-325.
22. (e) Fishbein, W. N.; Davis, J. I.; Winkert, J. W.; Strong, D. M. Levels of Adenosine Deaminase, AMP Deaminase, and Adenylate Kinase in Cultured Human Lymphoblast Lines: Exquisite Sensitivity of AMP Deaminase to Adenosine Deaminase Inhibitors. Biochem. Med. 1981, 26, 377-386.
23. (f) Van den Berghe, G.; Bontemps, F.; Hers, H.-G. Purine Catabolism in Isolated Rat Hepatocytes Influence of Coformycin. Biochem. J. 1980, 188, 913-920.
24. Cha, S.; Agarwal, R. P.; Parks, R. E., Jr. Tight Binding Inhibitors-II Non-Steady-State Nature of Inhibition of Milk Xanthine Oxidase by Allopurinol and Alloxanthine and of Human Erythrocytic Adenosine Deaminase by Coformycin. Biochem. Pharmacol. 1975, 24, 2187-2197.
25. Kredich, N. M.; Hershfield, M. S. In The Metabolic Basis of Inherited Disease; Scrivner et al., Eds.; McGraw-Hill: New York, 1989; pp 1045-1075.
26. Wolfenden, R. Analogue Approaches to the Structure of the Transition State in Enzyme Reactions. Acc. Chem. Res. 1972, 5, 10-18.
27. (a) Marrone, T. J.; Straatsma, T. P.; Briggs, J. M.; Wilson, D. K.; Quiocho, F. A.; McCammon, J. A. Theoretical Study of Inhibition of Adenosine Deaminase by (8R)-Coformycin and (8R)-Deoxycoformycin. J. Med. Chem. 1996, 39, 277-284.
28. (b) Kline, P. C.; Schramm, V. L. Electrostatic Potential Surfaces of the Transition State for AMP Deaminase and for (R)-Coformycin, a Transition State Inhibitor. J. Biol. Chem. 1994, 269, 22385-22390.
29. (c) Kati, W. M.; Acheson, S. A.; Wolfenden, R. A Transition State in Pieces: Major Contributions of Entropic Effects to Ligand Binding by Adenosine Deaminase. Biochemistry 1992, 31, 7356-7366.
30. See the following papers in this issue: (a) Kasibhatla, S. R.; Bookser, B. C.; Probst, G.; Appleman, J. R.; Erion, M. D. AMP Deaminase Inhibitors. 3. SAR of 3-(Carboxyarylalkyl)coformycin Aglycon Analogues. J. Med. Chem. 2000, 43, 1508-1518.
31. (b) Bookser, B. C.; Kasibhatla, S. R.; Erion, M. D. AMP Deaminase Inhibitors. 4. Further N3-Substituted Coformycin Aglycon Analogues. N3-Alkylmalonates as Ribose 5′-Monophosphate Mimetics. J. Med. Chem. 2000, 43, 1519-1524.
32. For literature relating to the synthesis of coformycin analogues, see ref 8 and: (a) Chan, E.; Putt, S. R.; Showalter, H. D. H.; Baker, D. C. Total Synthesis of (8R)-3-(2-Deoxy-β-D-eryrtropentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d] [1,3]diazepin-8-ol (Pentostatin), the Potent Inhibitor of Adenosine Deaminase. J. Org. Chem. 1982, 47, 3457-3464.
33. (b) Showalter, H. D. H.; Putt, S. R.; Borondy, P. E.; Shillis, J. L. Adenosine Deaminase Inhibitors. Synthesis and Biological Evaluation of (±)-3,6,7,8-Tetrahydro-3-[(2-hydroxyethoxy)methyl]imidazo[4,5-d][1,3]- diazepin-8-ol and Some Selected C-5 Homologues of Pentostatin. J. Med. Chem. 1983, 26, 1478-1482.
34. (c) Smal, E. Synthesis, Biosynthesis and Studies Related to Compounds of Interest in Cancer Chemotherapy. Ph.D. Dissertation, University of Alabama, 1985.
35. (d) Thomas, H. J.; Riordan, J. M.; Montgomery, J. A. The Synthesis of Coformycin from 5-Amino-1-β-D-ribofuranosylimidazole-4-carboxamide. Nucleosides Nucleotides 1986, 5, 431-439.
36. (e) Saville-Stones, E. A.; Turner, R. M.; Lindell, S. D.; Jennings, N. S.; Head, J. C.; Carver, D. S. Total Synthesis of Carbocyclic Analogues of Coformycin. Tetrahedron 1994, 50, 6695-6704.
37. (f) Truong, T. V.; Rapoport, H. Chirospecific Synthesis of the Tetrahydroimidazodiazepinol Aglycon of Pentostatin and Its Analogues. J. Org. Chem. 1993, 58, 6090-6096.
38. (g) Truong, T. V. Chirospecific Synthesis of Pentostatin and Its Analogues. Ph.D. Dissertation, University of California, Berkeley, 1989.
39. 1/2 min) 1 (0.3), 2 (3). (formula presented)
40. Al-Razzak, L. A.; Benedetti, A. E.; Waugh, W. N.; Stella, V. J. Chemical Stability of Pentostatin (NSC-218321), a Cytotoxic and Immunosuppressant Agent. Pharm. Res. 1990, 7, 452-460.
41. as for bisprotonated 7k′ were determined to be 6.5 and 2.1.
42. 1 Epoxide. J. Am. Chem. Soc. 1994, 116, 8863-8869.
43. (b) Pugmire, R. J.; Grant, D. M.; Townsend, L. B.; Robins, R. K. Carbon-13 Magnetic Resonance. XXII. The N-Methylpurines. J. Am. Chem. Soc. 1973, 95, 2791-2796.
44. The electrophile used to prepare 7i was synthesized according to a literature method: Shchaveleva, I. L.; Kochetkova, S. V.; Tsilevich, T. L.; Vladyko, G. V.; Korobchenko, L. V.; Boreko, E. I.; Smirnov, I. P.; Khorlin, A. A.; Gottikh, B. P.; Florent'ev, V. L. Preparation of Chloromethylalkylcarboxy Esters. Sov. J. Bioorg. Chem. 1990, 15, 523-527.
45. Compound 14b was prepared according to the method described by: (a) Chen, B.-C.; Lue, P. A Convenient Preparation of 5,5-Dialkyl Meldrum's Acids. Org. Prep. Proced. Int. 1992, 24, 185-188
46. and (b) Oikawa, Y.; Hirasawa, H.; Yonemitsu, O. Meldrum's Acid in Organic Synthesis. 1. A Convenient One-Pot Synthesis of Ethyl Indolepropionates. Tetrahedron Lett. 1978, 1759-1762 .
47. Rathke, M. W.; Lindert, A. The Reaction of Lithium N-Isopropylcyclohexylamide with Esters. A Method for the Formation and Alkylation of Ester Enolates. J. Am. Chem. Soc. 1971, 93, 2318-2320.
48. +] 455. For a similar observation see: Upton, C. L.; Beak, P. Dipole Stabilized Carbanions. Reactions of Benzoate Esters with Lithium 2,2,6,6-Tetramethylpiperidide. J. Org. Chem. 1975, 40, 1094-1098.
49. MacPhee, J. A.; Dubois, J.-E. Steric Limits to Ester Alkylation; Synthesis of Highly Hindered Esters via Hexamethylphosphoramide-favoured Enolization. J. Chem. Soc., Perkin Trans. 1 1977, 694-696.
50. For prior 5-lithiotetrazole chemistry see: (a) Yi, K. Y.; Yoo, S.-e. Synthesis of 5-Aryl and Vinyl Tetrazoles by the Palladium-Catalyzed Cross-Coupling Reaction. Tetrahedron Lett. 1995, 36, 1679-1682.
51. (b) Satoh, Y.; Marcopulos, N. Application of 5-Lithiotetrazoles in Organic Synthesis. Tetrahedron Lett. 1995, 36, 1759-1762.
52. Merkler, D. J.; Brenowitz, M.; Schramm, V. L. The Rate Constant Describing Slow-Onset Inhibition of Yeast AMP Deaminase by Coformycin Analogues Is Independent of Inhibitor Structure. Biochemistry 1990, 29, 8358-8364.
53. Schramm, V. L.; Baker, D. C. Spontaneous Epimerization of (S)-Deoxycoformycin and Interaction of (R)-Deoxycoformycin, (S)-Deoxycoformycin, and 8-Ketodeoxycoformycin with Adenosine Deaminase. Biochemistry 1985, 24, 641-646.
54. (a) Hampton, A.; Sasaki, T.; Perini, F.; Slotin, L. A.; Kappler, F. Design of Substrate-Site-Directed Irreversible Inhibitors of Adenosine 5′-Phosphate Aminohydrolase. Effect of Substrate Substituents on Affinity for the Substrate Site. J. Med. Chem. 1976, 19, 1029-1033.
55. (b) Merkler, D. J.; Schramm, V. L. Catalytic Mechanism of Yeast Adenosine 5′-Monophosphate Deaminase. Zinc Content, Substrate Specificity, pH Studies and Solvent Isotope Effects. Biochemistry 1993, 32, 5792-5799.
56. For X-ray crystallographic examples of this type of interaction, see: (a) Erion, M. D.; Niwas, S.; Rose, J. D.; Ananthan, S.; Allen, M.; Secrist, III, J. A.; Babu, Y. S.; Bugg, C. E.; Guida, W. C.; Ealick, S. E.; Montgomery, J. A. Structure-Based Design of Inhibitors of Purine Nucleoside Phosphorylase. 3. 9-Arylmethyl Derivatives of 9-Deazaguanine Substituted on the Methylene Group. J. Med. Chem. 1993, 36, 3771-3783.
57. (b) Guida, W. C.; Elliot, R. D.; Thomas, H. J.; Secrist, III, J. A.; Babu, Y. S.; Bugg, C. S.; Erion, M. D.; Ealick, S. E.; Montgomery, J. A. Structure-Based Design of Inhibitors of Purine Nucleoside Phosphorylase. 4. A Study of Phosphate Mimics. J. Med. Chem. 1994, 37, 1109-1114.